VIDEO: Comparable safety observed with aflibercept, photocoagulation in ROP
Click Here to Manage Email Alerts
Key takeaways:
- The phase 3 BUTTERFLEYE trial compared aflibercept vs. laser photocoagulation in infants with retinopathy of prematurity.
- A comparable good safety profile was observed in both patient groups.
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Darius M. Moshfeghi, MD, discusses results from the phase 3 BUTTERFLEYE trial.
The trial compared the efficacy and safety of intravitreal aflibercept injection with laser photocoagulation in infants with retinopathy of prematurity.
“The data showed that we didn’t meet our noninferiority outcome. However, the data was very clinically compelling,” Moshfeghi said. “Seventy-nine percent of infants in the aflibercept group met the primary outcome vs. 77% in the laser group.”
A good safety profile was observed in both groups, Moshfeghi said.
Collapse
Moshfeghi DM. Effects of intravitreal aflibercept versus laser photocoagulation for retinopathy of prematurity: Results from the phase 3 BUTTERFLEYE trial. Presented at: Association for Research in Vision and Ophthalmology meeting; April 23-27, 2023; New Orleans.
Read more about
Click Here to Manage Email Alerts